Getting diagnosed with cancer is a life-changing alarming news, but battling the illness is another story. Luckily, these days, patients are now presented with a new hope in the form of innovative cures.
Thanks to hard-working oncologists and biotech companies, these modern cures are replacing chemotherapy as a solution and they are currently shaping the future of curing cancer in the most painless and effective way possible.
Tina Nova, senior vice president of oncology at Illumina, discussed the positive results of liquid biopsy in her essay on Wired. Liquid biopsy is a test that will detect tumor DNA circulating in the blood even before it develops into a cancerous tumor. Compared to the painful tissue biopsy, liquid biopsy does not give the patient any physical pain.
Nova hopes that through liquid biopsy, oncologists will be able to detect cancer at its earliest stage, earlier than ever before. According to Nova, liquid biopsy is “the most exciting” thing she has ever encountered during her career. Illumina is currently on its research phase of building a library of circulating tumor DNA. These DNA are the genetic fragments that Illumina hopes they can detect through a simple blood test.
There have been many positive results about Immunotherapy and how it attacks cancer by strengthening the patient’s own immune system. Some reports deem the cure “miraculous,” while others see it as a bright sign of hope. A report by Medscape revealed how a 49-year-old woman with metastatic melanoma was led to the recovery road by immunotherapy.
The report stated that after a single dose of an experimental immunotherapy combination, the tumor under her left breast disappeared. Clinicians from the Memorial Sloan Kettering Cancer Center in New York City referred to the development as “remarkable,” in a letter published by the New England Journal of Medicine.
Biotech companies around the world are starting to develop different kinds of immunotherapy cures for different kinds of cancers, and one of them is California-based Nascent Biotech, Inc. (OTC:NBIO). Nascent has developed Pritumumab, a natural human antibody that has been used to treat 250 cancer patients. The antibody’s Phase II clinical trials in Japan for patients with brain cancer showed an overall response between 25 to 30 percent, with survivors going beyond 5 years into remission.
Another latest cancer cure is the use of poliovirus to attack cancerous tumors inside the body. Called glioblastoma multiforme (GBM), the cure was given a closer look by the show 60 Minutes during its 10-month clinical trial. Molecular biologist Dr. Matthias Gromeier saw what the poliovirus can do to the human body and thought that it could harness the same effect on brain tumors.
GBM treatment is done by injecting the virus directly into the brain tumor, once there, the virus increases the body’s immune response against tumor cells.
“So cancers, all human cancers, they develop a shield or shroud of protective measures that make them invisible to the immune system. And this is precisely what we try to reverse with our virus. By infecting the tumor, we are actually removing this protective shield,” Dr. Gromeier rold 60 Minutes, as reported by The Market Business.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
The coronavirus has caused a rise in cannabis prices
According to a report published last year by the National Drug Plan, one in ten Spanish adults use hashish or...
Bitcoin hash rate is slumping due to uncertainty
While the Bitcoin price started to slowly increase again, the BTC hash rate is plummeting. According to blockchain.com, the maximum...
Italian biotech companies entered the race to find a vaccine against COVID-19
Several Italian biotech companies, such as Irbim, ReiThera and Takis, have entered the international race to develop a vaccine that...
Why should banks and FinTech operators ally?
Crowdfunding lending platforms in Italy have put together availability of capital and technology and automation to support SMEs and families...
Several organizations accept donations in cryptocurrencies to fight the pandemic
As a consequence of the situation caused by the coronavirus pandemic in the world, interesting events related to Bitcoin and...
- Business7 days ago
Unicorn or not: why the post Coronavirus startup scene will require a “New Startup Deal”
- Biotech7 days ago
Biontech to receive €120 million for the research of a COVID-19 vaccine
- Business7 days ago
Italy closes all non-essential production activities amid the coronavirus crisis
- Featured6 days ago
Fintech is the bet of bankarization in the digital era